STUDY OF PREDICTIVE VALUE OF RAD51 EXPRESSION FOR THE EFFECTIVENESS OF PLATINUM-BASED THERAPY OF HIGH-GRADE SEROUS OVARIAN CARCINOMA
DOI:
https://doi.org/10.15407/exp-oncology.2026.02.133Keywords:
ovarian cancer, RAD51, platinum-containing chemotherapy, potential predictor of platinum sensitivity, homologous repair systemAbstract
Background. The search for novel markers of predictive significance is an important issue in the management of ovarian cancer (OC) patients. Recently, the expression of the RAD51 protein, involved in homologous DNA repair has been shown to be predictive of platinum chemotherapy response in OC patients. Aim. To establish the relationship between the level of RAD51 protein expression in patients with high-grade serous ovarian carcinoma (SOC) after neoadjuvant platinum chemotherapy and the frequency of recurrence, disease progression, and relapse-free survival. Materials and Methods. RAD51 status was assessed in the archival histological material of 30 patients with SOC of stage III who received perioperative platinum-based chemotherapy. RAD51 expression was analyzed using a double-staining technique in samples containing at least 100 geminin-positive tumor cells. RAD51 status was considered positive if > 10% of geminin-positive nuclei were positive for RAD51. Results. In 16 of 30 cases, the tumor had a RAD51–positive status (homologous repair proficient, HRP), and in 14 — RAD51-negative (homologous repair deficient, HRD). We found that the risk of disease progression in patients with RAD51 HRP status was 3.42 times higher compared to patients with RAD51 HRD status (HR = 3.42; 95% CI 1.38—8.46; p = 0.008). In SOC patients with RAD51 HRP status, a significantly higher (p < 0.001) rate of disease progression over 3 to 12 months of postoperative observation compared to patients with RAD51 HRD status was detected. Conclusions. RAD51 expression is predictive for the response of highgrade SOC to platinum therapy.
References
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. https://doi.org/10.3322/caac.21834
Lheureux S, Gourley C, Vergote I, et al. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240-1253. https://doi.org/10.1016/S0140-6736(18)32552-2
Eisenhauer EA. Real-world evidence in the treatment of ovarian cancer. Ann Oncol. 2017;28(suppl 8):viii61-viii65. https://doi.org/10.1093/annonc/mdx443
Wu YB, Li SY, Liu JY, et al. Long non-coding RNA NRSN2-AS1 promotes ovarian cancer progression through targeting PTK2/β-catenin pathway. Cell Death Dis. 2023;14(10):696. https://doi.org/10.1038/s41419-023-06214-z
Prat J; FIGO Committee on Gynecologic Oncology. FIGO’s staging classification for cancer of the ovary, fallopian tube, and peritoneum: Abridged republication. J Gynecol Oncol. 2015;26(2):87-89. https://doi.org/10.3802/jgo.2015.26.2.87
American Cancer Society: Key statistics for ovarian cancer, 2019. https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html
Kim J, Park EY, Kim O, et al. Cell origins of high-grade serous ovarian cancer. Cancers (Basel). 2018;10(11):433. https://doi.org/10.3390/cancers10110433
Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-775. https://doi.org/10.1158/1078-0432
Norquist BM, Brady MF, Harrell MI, et al. Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group study. Clin Cancer Res. 2018;24(4):777-783. https://doi.org/10.1158/1078-0432.CCR-17-1327
Miller RE, Leary A, Scott CL, et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol. 2020;31(12):1606-1622. https://doi.org/10.1016/j.annonc.2020.08.2102
Konstantinopoulos PA, Ceccaldi R, Shapiro GI, et al. Homologous recombination deficiency: Exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2015;5(11):1137-1154. https://doi.org/10.1158/2159-8290.CD-15-0714
Rebbeck TR, Mitra N, Wan F, et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015;313(13):1347-1361. https://doi.org/10.1001/jama.2014.5985
Frey MK, Pothuri B. Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: A review of the literature. Gynaecol Oncol Res Pract. 2017;4:4. https://doi.org/10.1186/s40661-017-0039-8
Swisher EM, Lin KK, Oza AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): An international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75-87. https://doi.org/10.1016/S1470-2045(16)30559-9
Fuh K, Mullen M, Blachut B, et al. Homologous recombination deficiency real-time clinical assays, ready or not? Gynecol Oncol. 2020;159(3):877-886. https://doi.org/10.1016/j.ygyno.2020.08.035
Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, et al. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. EMBO Mol Med. 2018;10(12):e9172. https://doi.org/10.15252/emmm.201809172
Feng Y, Wang D, Xiong L, et al. Predictive value of RAD51 on the survival and drug responsiveness of ovarian cancer. Cancer Cell Int. 2021;21(1):249. https://doi.org/10.1186/s12935-021-01953-5
Hill SJ, Decker B, Roberts EA, et al. Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids. Cancer Discov. 2018;8(11):1404-1421. https://doi.org/10.1158/2159-8290.CD-18-0474
Compadre AJ, van Biljon LN, Valentine MC, et al. RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer. Clin Cancer Res. 2023;29(13):2466-2479. https://doi.org/10.1158/1078-0432.CCR-22-3335
Cruz C, Castroviejo-Bermejo M, Gutiérrez-Enríquez S, et al. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol. 2018;29(5):1203-1210. https://doi.org/10.1093/annonc/mdy099
van Wijk LM, Kramer CJH, Vermeulen S, et al. The RAD51-FFPE test; Calibration of a functional homologous recombination deficiency test on diagnostic endometrial and ovarian tumor blocks. Cancers (Basel). 2021;13(12):2994. https://doi.org/10.3390/cancers13122994
van Wijk LM, Nilas AB, Vrieling H, et al. RAD51 as a functional biomarker for homologous recombination deficiency in cancer: A promising addition to the HRD toolbox? Expert Rev Mol Diagn. 2022;22(2):185-199. https://doi.org/10.1080/14737159.2022.2020102
Byrum AK, Vindigni A, Mosammaparast N. Defining and modulating ‘BRCAness’. Trends Cell Biol. 2019;29(9):740-751. https://doi.org/10.1016/j.tcb.2019.06.005
Llop-Guevara A, Loibl S, Villacampa G, et al. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial. Ann Oncol. 2021;32(12):1590-1596. https://doi.org/10.1016/j.annonc.2021.09.003
Eikesdal HP, Yndestad S, Elzawahry A, et al. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Ann Oncol. 2021;32(2):240-249. https://doi.org/10.1016/j.annonc.2020.11.009
Blanc-Durand F, Yaniz E, Genestie C, et al. Evaluation of a RAD51 functional assay in advanced ovarian cancer, a GINECO/GINEGEPS study. J Clin Oncol. 2021;39(15 Suppl):5513. https://doi.org/10.1200/JCO.2021.39.15_suppl.5513
Blanc-Durand F, Yaniz-Galende E, Llop-Guevara A, et al. A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer. Gynecol Oncol. 2023;171:106-113. https://doi.org/10.1016/j.ygyno.2023.01.026
Pellegrino B, Herencia-Ropero A, Llop-Guevara A, et al. Preclinical in vivo validation of the RAD51 test for identification of homologous recombination-deficient tumors and patient stratification. Cancer Res. 2022;82(8):1646-1657. https://doi.org/10.1158/0008-5472.CAN-21-2409
Graeser M, McCarthy A, Lord CJ, et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res. 2010;16(24):6159-6168. https://doi.org/10.1158/1078-0432.CCR-10-1027
Tumiati M, Hietanen S, Hynninen J, et al. A functional homologous recombination assay predicts primary chemotherapy response and long-term survival in ovarian cancer patients. Clin Cancer Res. 2018;24(18):4482-4493. https://doi.org/10.15252/emmm.202013366
Feng Z, Zhu C, Zhang X, et al. Comprehensive evaluation of genomic and functional assays for homologous recombination deficiency with high-grade epithelial ovarian cancer: Platinum sensitivity and prognosis. Int J Gynecol Cancer. 2025;35(1):100031. https://doi.org/10.1016/j.ijgc.2024.100031
Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4(4):307-320. https://doi.org/10.1038/nrd1691
Gomez-Puerto D, Llop-Guevara A, Cruellas M, et al. Genetic and functional homologous repair deficiency as biomarkers for platinum sensitivity in TNBC: A case report. Front Oncol. 2022;12:963728. https://doi.org/10.3389/fonc.2022.963728
Kausar MA, Alshammari KF, Alenazi F, et al. RAD51 and PALB2 in precision oncology: Clinical implications for HRD associated breast and ovarian cancers (Review). Int J Oncol. 2025;67(2):65. https://doi.org/10.3892/ijo.2025.5771
Submitted: January 29, 2026
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
